Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)

European Journal of Cancer Part A

Volumn 33, Issue 7, 1997, Pages 1017-1024

  Thurlimann B ^a   Castiglione, M ^a   Hsu Schmitz, S F ^a   Cavalli, F ^a   Bonnefoi, H ^a   Fey, M F ^a   Morant, R ^a   Lohnert T ^a   Goldhirsch, A ^a  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

Author keywords

Aromatase inhibitor; Breast cancer; Formestane; Megestrol acetate

Indexed keywords

FORMESTANE; MEGESTROL ACETATE;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT FAILURE; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CROSS-OVER STUDIES; FEMALE; HUMANS; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; REMISSION INDUCTION; TAMOXIFEN; TIME FACTORS; TREATMENT FAILURE;

EID: 0343924363     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00105-6     Document Type: Article

References (21)

1. Cooleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mortality. IARC Publ. 121, 1993.
2. Levy F, La Vecchia C, Schüler G, Bopp M, Tschopp A. Occurrence of breast cancer: facts and trends in. National Cancer Control Program. Breast Cancer Swiss Federal Office of Public Health and Swiss Cancer League. Bern, Switzerland, 1996, 5-7.
3. Levy F, La Vecchia C, Lucchini F, Randimpison L. Epidemiology of cancer in Switzerland. Lausanne, Switzerland. Assoc of Swiss Cancer Registries, 1994.
4. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 1986, 104-107.
5. Toyce C. Formestane. Drugs of the Future (7) 1993, 18, 599-600.
6. Pérez Carrion R, Alberola Candel V, Calabresi F, et al. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol (Suppl.7) 1994, 5, 19-24.
7. Cole MP, Jones CTA, Todd IDJ. A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46, 474. Br J Cancer 1971, 25, 270-275.
8. Muss BH, Case LD, Atkins JN, et al. Tamoxifen versus high dose medroxyprogesterone acetate as an initial endocrine therapy for patients with metastatic breast cancer. Piedmont Association Study. J Clin Oncol 1994, 12, 1630-8.
9. Gale KE, Anderson JW, Tormey DC, et al. Hormonal treatment for metastatic breast cancer. An Eastern Cooperative Oncology Group phase III trial comparing aminoglutethimide to tamoxifen. Cancer (2) 1994, 73, 354-61.
10. Falkson CI, Falkson HC. A randomised study of CGS 16 949A (fadrozole) versus tamoxifen in previously untreated post-menopausal patients with advanced metastatic breast cancer. Ann Oncol 1996, 7, 465-469.
11. Thürlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16 949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 1996, 7, 471-479.
12. Howell A, Mackintosh J, Jones M, Redford J, Wagstaff J, Sellwood RA. The definition of the "No Change" category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988, 24, 1567-1572.
13. Robertson JFR, Willsher P, Cheung KL, Blarney RW. The clinical relevance of static disease for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 1996, 32A, 53 (Abstract).
14. Living with advanced breast cancer hormone treatment. European Oncology Nursing Society EONS, Brussels, Belgium, and Tayler Nelson ABG, PLG, Health Care, Epsom, U.K. July 1996.
15. Castliglione-Gertsch M, Pampallona S, Marini M, et al. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 1993, 4, 735-740.
16. Rose C. When tamoxifen fails in the treatment of advanced breast cancer - which endocrine therapy comes next?. In Rubens RD, ed. Advanced Breast Cancer Reassessing Hormone Therapy. The Partenon Publishing Group, London, New York, 1996, 33-41.
17. Ciba-Geigy (Novartis), Data on file, 1996.
18. Arimidex Study Group. Randomized trial comparing two doses of the new selected aromatase inhibitor anastrozole with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996, 32A, 404-412.
19. Zeneca, Data on file, 1996.
20. Dombernowsky P, Smith I, Falkson G, et al. for the Letrozole International Trial Group (AR/BC 2) 1996. Proc ASCO. Poster No. 64.
21. Murray P, Pitt P, Roth C. Treatment of advanced breast cancer with formestane. Ann Oncol (7) 1994, 5, 11-13.